Emergent BioSolutions (EBS) Cash & Equivalents Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 29.96% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 20.41% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -2.73% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.02% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 3.22% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 52.71% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 36.93% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 10.41% |
| 10 | Emergent BioSolutions | 383.54 Mn | 222.04 Mn | 84.10 Mn | -28.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.04% |
| Dec 31, 2025 | -31.63% |
| Sep 30, 2025 | 0.63% |
| Jun 30, 2025 | -9.29% |
| Mar 31, 2025 | -30.06% |
| Dec 31, 2024 | -44.31% |
| Sep 30, 2024 | -28.13% |
| Jun 30, 2024 | -46.20% |
| Mar 31, 2024 | -47.67% |
| Dec 31, 2023 | -43.56% |
| Sep 30, 2023 | -40.41% |
| Jun 30, 2023 | -30.92% |
| Mar 31, 2023 | 33.33% |
| Dec 31, 2022 | 56.45% |
| Sep 30, 2022 | 963.99% |
| Jun 30, 2022 | 1,114.30% |
| Mar 31, 2022 | 47.00% |
| Dec 31, 2021 | 72.52% |
| Sep 30, 2021 | 5.97% |
| Jun 30, 2021 | 654.23% |